Olink Target 96 Organ Damage Panel

What is the Olink Target 96 Organ Damage Panel  

Customized panel for human

The Olink Target 96 Organ Damage Panel accurately quantifies proteins, with detailed biomarker data available on our website. Employing advanced Biomarker technology, the panel evaluates 92 proteins via a three-stage workflow: incubation, extension/amplification, and detection. In the incubation phase, DNA-labeled antibody pairs bind target proteins overnight. The next day, extension and amplification create unique DNA reporter sequences, followed by preamplification using standard PCR. Detection is conducted via high-throughput real-time qPCR on the Olink Signature Q100 System to quantify DNA sequences. Samples were randomized across plates to ensure unbiased results. Data underwent strict quality control and normalization, using internal and interplate controls to manage batch variability. Protein levels are expressed as normalized protein expression (NPX) values on a log2 scale for accurate interpretation.

Features of the pane

• Species: Primarily validated for human proteins; cross-reactivity with other species is not guaranteed.  
• Proteins: Measures 92 protein biomarkers simultaneously in a single assay.
• Sample: Requires just 1µL of plasma, serum, or comparable biofluids.  
• Readout: Delivers data in normalized protein expression (NPX) units, ensuring precise quantification of protein levels.
• Platform: Optimized for use with the Olink Signature Q100 platform for efficient and reliable analysis.

List of 92 human derived biomarkers

Protein category

The Olink Target 96 Organ Damage Panel includes 92 proteins categorized into nine main groups:

the enzymes (25), Signal Transduction Proteins (13), Cytoskeleton and Cell Motility (5), Immune System Proteins (6), Apoptosis and Cell Cycle (5), Transcriptional Regulation (4), Metabolism-Related Proteins (5), Cell Adhesion and ECM Proteins (5), and other functional proteins (24). These protein biomarkers were selected based on the dynamic range in the sample and the degree of intimacy with the process of organ damage. Several international bioinformatics databases (Uniprot, Human Protein Atlas, Gene Ontology, and DisGeNET) have classified and summarized the proteins contained in myocardial metabolic panels, including responses to stress, regulation of cell proliferation, cell cycle, and cell death/apoptosis.

Table. List of Olink Target 96 Organ Damage Panel.

Protein Functions

Biological process

Primarily associated with immune systerm diseases, signal transduction, qnd cytokine signaling in immune system.

Disease area

Primarily associated with metsbolic, carsiovascula, cancer, imuune, and diabetes mellitus.

Workflow of Olink Proteomics

Demo Results of Olink Data

(Figures come from Ding, R., et al. 2024)

The bar chart displayed the number of proteins.

Volcano plots of differentially expressed proteins.

Heatmap of differentially expressed proteins.

Case Study

Comparative Analysis of Circulating Noncoding RNAs Versus Protein Biomarkers in the Detection of Myocardial Injury

Journal: Circulation research
Year: 2019

• Background
• Results

Non-coding RNA (ncrna), including microRNA (miRNA), circular RNA (circRNA), and long non-coding RNA (LNcrna), is considered a novel biomarker of myocardial injury. Their release kinetics have not been explored without heparin interference, and their relationship with cardiac muscle protein biomarkers has not been discovered. Compare ncRNA types in heparinase-treated samples with established and emerging protein biomarkers of myocardial injury.

qPCR and ELISA detect circulating mirna and protein, respectively. To rule out the effect of different assays on the observed release kinetics, we used a proximity expansion assay (PEA) to assess cTnI. PEA combines dual antibody-based detection with qpCR-based quantification. Although PEA is less sensitive for the detection of cTnI compared to hs-cTnT, both assays show a similar temporal distribution of cTn release after TASH (Figure 4C). The PEA determination of cTnI is not affected by heparin (online panel X) because a very small sample volume is required compared to the miRNA assay (plasma μL for cTnI, plasma μL for miRNA).

Figure 1. The test results showed similarity Time profile release after TASH (Figure 4C).
(Schulte, C, et al. 2019)

FAQs

Why Creative Proteomics

Dynamic Biomarker Validation Suites

ELISA/MSD validation is provided to reduce false positives and enhance research reliability.

Adaptive Cohort Stratification Tools

Custom algorithms are developed to stratify patients by proteomic signatures, optimizing clinical trial design.

Olink Biomarker Validation

ELISA/MSD validation is utilized to strengthen fibrosis and immuno-oncology research.

Interactive NPX Exploration

Interactive NPX data analysis is supported to accelerate research progress.

Sample Requirements

References

1. Kugler, S., Hahnefeld, L., Kloka, J. A., et al. (2024). Short-term predictor for COVID-19 severity from a longitudinal multi-omics study for practical application in intensive care units. Talanta, 268(Pt 1), 125295. https://doi.org/10.1016/j.talanta.2023.125295 
2. Schulte, C., Barwari, T., Joshi, A., et al. (2019). Comparative Analysis of Circulating Noncoding RNAs Versus Protein Biomarkers in the Detection of Myocardial Injury. Circulation research, 125(3), 328–340. https://doi.org/10.1161/CIRCRESAHA.119.314937   
3. Ding, R., Wu, L., Wei, S., et.al. (2024). Multi-targeted olink proteomics analyses of cerebrospinal fluid from patients with aneurysmal subarachnoid hemorrhage. Proteome science, 22(1), 11. https://doi.org/10.1186/s12953-024-00236-x